GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients


Schotten, Clemens, Ostertag, Bastian, Sowa, Jan-Peter, Manka, Paul, Bechmann, Lars P, Hilgard, Gudrun, Marquardt, Claudio, Wichert, Marc, Toyoda, Hidenori, Lange, Christian M et al (show 4 more authors) (2021) GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients. Pharmaceuticals, 14 (8). p. 735.

[img] Text
manuscript.v7.docx - Author Accepted Manuscript
Download (463kB)

Abstract

<jats:p>Despite vaccination programs and direct antiviral treatments, the incidence of virus-related hepatocellular carcinoma (HCC) remains high, while ultrasound-based detection rates for early-stage HCC is continuously low. To address this insufficiency, we set out to characterize whether the GALAD score, which incorporates gender, age, and serum levels of AFP, AFP isoform L3 (AFP-L3), and des-gamma-carboxy-prothrombin (DCP), can improve early-stage HCC detection in a Caucasian HBV/HCV cohort. In a retrospective German single-center study, 182 patients with HBV, 223 with HCV and 168 with other etiology (OE) of chronic liver disease (CLD) were enrolled. HCC was confirmed in 52 HBV, 84 HCV and 60 OE CLD patients. The diagnostic performance of the single biomarkers in HCC detection was compared to the GALAD model. At initial diagnosis, most patients were at (very) early BCLC 0 (n = 14/7%) or A (n = 56/29%) or intermediate stage BCLC B (n = 93/47%) HCC in all three subgroups. In the BCLC 0/A cohort, GALAD exhibited an AUC of 0.94 discriminating HCC from non-HCC, surpassing AFP (AUC 0.86), AFP-L3 (AUC 0.83) and DCP (AUC 0.83). In the HBV population, GALAD achieved an AUC of 0.96, in HCV an AUC of 0.98 and in OE an AUC of 0.99, clearly superior to the biomarkers alone. Furthermore, in HCV patients GALAD showed a significantly higher specificity (89%) versus AFP (64%) alone. In chronic viral hepatitis, the GALAD model showed superior performance in detection of early-stage HCC, while exhibiting higher specificity in HCV patients compared to AFP alone. We conclude that the GALAD score shows potential for HCC surveillance in Caucasian HBV/HCV patients.</jats:p>

Item Type: Article
Uncontrolled Keywords: hepatocellular carcinoma, HCC, chronic hepatitis B, chronic hepatitis C, HBV, HCV, AFP, AFP-L3, DCP, GALAD
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 02 Aug 2021 09:55
Last Modified: 18 Jan 2023 21:35
DOI: 10.3390/ph14080735
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3131582
Dimensions
Altmetric
CORE (COnnecting REpositories)